tradmap

FTLF FITLIFE BRANDS, INC.

$8.26 +4.69%

Data as of close

Healthcare · Medicinal Chemicals & Botanical Products

FITLIFE BRANDS, INC. (FTLF) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $78 million. Shares last traded at $8.26, 58.4% below their 52-week high. Over the past year the stock is down 58.6%. FTLF trades at a price-to-earnings ratio of 12.45, above the Medicinal Chemicals & Botanical Products median of 12.16. Net profit margin is 6.2%, above the peer median of -8.8%. Revenue declined 75.3% year over year.

Market Cap
$78M
Shares Out
9.4M
EPS (TTM)
$0.19
P/E (TTM)*
12.45
P/S Ratio
0.77
P/B Ratio
1.64
Dividend / Share
—
Dividend Yield
—
52-Week High
$19.88
52-Week Low
$7.89
Volume (venue)
415
Avg Vol (3m, venue)
135.302

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-1.08%
1M
-9.53%
3M
-18.30%
6M
-11.80%
YTD
-49.00%
1Y
-58.57%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. FTLF split history →

Technicals

RSI (14)
42.24
SMA (50)
$9.18
SMA (200)
$11.36
Price vs SMA50
-10.04%
Price vs SMA200
-27.30%
ATR (14)
$0.28

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$101M
Net Income
$6M
Gross Margin
36.5%
Operating Margin
10.9%
Net Margin
6.2%
Return on Equity
13.2%
Return on Assets
6.1%
Current Ratio
1.46
Debt / Equity
0.98
Revenue Growth (YoY)
-75.3%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $0.20 2026-08-13
Q1 2026 $0.17 2026-05-14
Q4 2025 (derived) -$0.27 2026-03-31
FY 2025 $0.20 2026-03-31
Q3 2025 $0.09 2025-11-13
Q2 2025 $0.18 2025-08-14

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Medicinal Chemicals & Botanical Products peers

FTLF vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

P/E vs peers
12.45 / 12.16 med
+2% premium
P/S vs peers
0.77 / 0.58 med
+33% premium
Net margin vs peers
6.2% / -8.8% med
above median
1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.4B———-10.70%
RGCRegencell Bioscience Holdings Ltd$3.1B———-5.00%
TRLVTrulieve Cannabis Corp.$2.1B—1.88-41.8%+8.19%
CRONCronos Group$1.2B17.646.8939.1%+1.52%
TLRYTilray Brands$375M—0.39-17.1%+0.40%
SNDLSNDL Inc.$337M———+2.81%
CGCCanopy Growth$288M—1.37-80.0%+4.07%
USNAUSANA HEALTH SCIENCES INC$271M—0.30-2.4%+2.69%
ACBAurora Cannabis$237M———+3.94%
GLASGlass House Brands Inc.$192M—1.05-16.3%+6.85%
NAGENiagen Bioscience, Inc.$190M11.881.4712.4%+2.56%
MDWDMediWound Ltd.$173M———+1.35%
FTLFFITLIFE BRANDS, INC.$78M12.450.776.2%+4.69%
BTMDbiote Corp.$33M5.560.183.2%+1.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.